Kenneth West, a former affiliate of Honeywell International Inc., filed a Form 144 notice of proposed sale on November 2, 2026, covering 1,131 shares of Honeywell common stock with an aggregate market value of $253,886.88.
Donnelley Financial Solutions, Inc. officer Craig D. Clay filed a Form 144 notice on November 2, 2026, disclosing a proposed sale of 54,018 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.
Donnelley Financial Solutions, Inc. officer Kami S Turner filed a Form 144 notice on November 2, 2026, proposing the sale of 12,100 shares of common stock acquired through the exercise of stock options under a registered plan.
Robert Mears, an officer of Atomera Incorporated, filed a Form 144 notice of proposed sale on November 2, 2026, indicating his intent to sell 1,000 shares of Atomera common stock on NASDAQ.
World Kinect Corp officer Michael J. Kasbar filed a Form 144 notice of proposed sale with the SEC on November 2, 2026, disclosing his intent to sell 10,000 shares of World Kinect common stock through Merrill Lynch on the NYSE.
Super Group (SGHC) Limited officer Kristy Ross filed a Form 144 notice of proposed sale of 2,724 shares of common stock, dated November 2, 2026, with J.P. Morgan Securities LLC named as broker.
Rimini Street, Inc. officer Steven Hershkowitz filed a Form 144 notice on November 2, 2026, disclosing a proposed sale of 42,482 shares of common stock acquired through a stock option exercise on the same date.
Luke Roy Swanson, an officer of Ibotta, Inc., filed a Form 144 notice on November 2, 2026, disclosing a proposed sale of 10,131 Class A shares through Fidelity Brokerage Services LLC on NYSE:IBTA.
Marisa Daspit, Chief People Officer of Ibotta, Inc., filed a Form 4 on November 2, 2026, reporting the sale of 246 shares of Class A Common Stock across two transactions on October 29 and October 30, 2026, under a Rule 10b5-1 trading plan.
Director Jason Aryeh filed a Form 144 notice on November 2, 2026, disclosing a proposed sale of 700 shares of Ligand Pharmaceuticals Inc Class B common stock originally acquired in 2019.